370 results about "Cholera" patented technology

A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus or parasite. In a particular embodiment, the amino acid 29 is histidine. The mutant cholera holotoxin may contain at least one additional mutation in the A subunit at a position other than amino acid 29. The antigenic composition may include a second adjuvant in addition to the mutant cholera holotoxin.

The invention relates to a special micro-fluidic chip for cholera diagnosis with one-dimensional self-assembly magnetic bead chain electrodes, belonging to the field of testing. Rapid diagnosis of fulminating infectious disease cholera with low cost is one of many expectations in the development of medical technology, and the invention provides a micro-fluidic chip for simultaneously detecting and rapidly diagnosing cholera by using multiple characteristic antibodies of cholera. The chip is provided with three micro liquid storage tanks, and the invention is characterized in that capillary passages in parallel configuration contain in the chip, the parallel configuration contains four micro-passages that are mutually in parallel, four magnetic bead chain working electrodes are respectively installed inside the four micro-passages, the surface substances of the four magnetic bead chain working electrodes are respectively four antibody substances that are cholera TP0821 antibody, cholera TP0319 antibody, cholera TP0624 antibody and cholera O139 mycoprotein antibody. The integrated structure and the appearances of specific magnetic bead chain working electrodes facilitate to improve the diagnosis efficiency of cholera diseases.

The invention relates to a multi-channel chip for cholera diagnosis based on a structural conductive macromolecular material technology, belonging to the test field. The invention aims to aid rapid and low-cost fulminating infectious disease cholera diagnosis which is one of medical technical progress expectations. The chip is provided with three micro liquid storage tanks and is characterized bycomprising capillary channels in parallel construction containing four micro channels mutually connected in parallel; four fibrous working electrodes are respectively mounted in the four micro channels; and four antibody substances, i.e. a cholera TP0821 antibody, a cholera TP0319 antibody, a cholera TP 0624 antibody and a cholera TP0139 antibody are respectively arranged on the surfaces of the four fibrous working electrodes which are originally made of a thermal-decomposition conductive macromolecular material. The chip has low cost and multiple channels.

Transgenic chloroplast technology could provide a viable solution to the production of Insulin-like Growth Factor I (IGF-I), Human Serum Albumin (HSA), or interferons (IFN) because of hyper-expression capabilities, ability to fold and process eukaryotic proteins with disulfide bridges (thereby eliminating the need for expensive post-purification processing). Tobacco is an ideal choice because of its large biomass, ease of scale-up (million seeds per plant), genetic manipulation and impending need to explore alternate uses for this hazardous crop. Therefore, all three human proteins will be expressed as follows: a) Develop recombinant DNA vectors for enhanced expression via tobacco chloroplast genomes b) generate transgenic plants c) characterize transgenic expression of proteins or fusion proteins using molecular and biochemical methods d) large scale purification of therapeutic proteins from transgenic tobacco and comparison of current purification/processing methods in E. coli or yeast e) Characterization and comparison of therapeutic proteins (yield, purity, functionality) produced in yeast or E. coli with transgenic tobacco f) animal testing and pre-clinical trials for effectiveness of the therapeutic proteins. Mass production of affordable vaccines can be achieved by genetically engineering plants to produce recombinant proteins that are candidate vaccine antigens. The B subunits of Enteroxigenic E. coli (LTB) and cholera toxin of Vibrio cholerae (CTB) are examples of such antigens. When the native LTB gene was expressed via the tobacco nuclear genome, LTB accumulated at levels less than 0.01% of the total soluble leaf protein. Production of effective levels of LTB in plants, required extensive codon modification. Amplification of an unmodified CTB coding sequence in chloroplasts, up to 10,000 copies per cell, resulted in the accumulation of up to 4.1% of total soluble tobacco leaf protein as oligomers (about 410 fold higher expression levels than that of the unmodified LTB gene). PCR and Southern blot analyses confirmed stable integration of the CTB gene into the chloroplast genome. Western blot analysis showed that chloroplast synthesized CTB assembled into oligomers and was antigenically identical to purified native CTB. Also, GM1,-ganglioside binding assays confirmed that chloroplast synthesized CTB binds to the intestinal membrane receptor of cholera toxin, indicating correct folding and disulfide bond formation within the chloroplast. In contrast to stunted nuclear transgenic plants, chloroplast transgenic plants were morphologically indistinguishable from untransformed plants, when CTB was constitutively expressed. The introduced gene was stably inherited in the subsequent generation as confirmed by PCR and Southern blot analyses. Incrased production of an efficient transmucosal carrier molecule and delivery system, like CTB, in transgenic chloroplasts makes plant based oral vaccines and fusion proteins with CTB needing oral administration a much more practical approach.

The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.

The invention provides a feed additive prepared from traditional Chinese medicines and used for preventing and treating common diseases of chickens. The feed additive is prepared from the following raw medicines by weight: honeysuckle, rhizoma belamcandae, rhizoma atractylodis, hawthorns, baical skullcap root, rhizoma coptidis, amur corktree bark, radix astragali, radix isatidis, rabdosia rubescens and dandelions. A preparation method of the feed additive is characterized by mixing the above raw medicines and then grinding the mixture or respectively grinding the above raw medicines and then mixing the ground raw medicines. The feed additive has the functions of strengthening body resistance and eliminating evil, clearing away heat and eliminating toxins, diminishing inflammation and strengthening stomach and killing bacteria and pests. By being mixed into the daily feed, the feed additive enhances the immunity of the chicken bodies, improves the disease resistance and has good prevention and treatment effects on common diseases of chickens such as bird flu, newcastle disease, salpingitis, white diarrhea, cholera, ascariasis, laryngotracheitis, coccidiosis, escherichia coli and the like. Through applications, the feed additive has the advantages of good prevention and treatment effects, no toxic or side effect, easily obtained raw materials and low price.

The invention relates to a culture medium for a normal epithelial cell of a human or mammal, primary separation culture, subculture, 3D gas-liquid culture and 3D matrigel culture methods, the normal epithelial cell generated by using the culture medium and the culture methods and application of the normal epithelial cell to a toxicological evaluation system. The culture medium is prepared by mixing DMEM and Ham's F-12NUTRIENT MIX according to the volume ratio of 3:1 and also adding 4-6% of fetal calf serum, 1-3nM triiodothyronine, 0.4-0.65% of insulin-transferrin-selenium reagent, 4-6mu g/ml transferrin, 9-11ng/mL epidermal growth factors, 0.3-0.5mu g/mL hydrocortisone, 0.5-1.5nM cholera toxin, 0.4-0.6mu g/mL amphoterrible B, 35-45mu g/mL gentamicin, 45-55nM calpeptin, 35-45ng/ml recombinant human IL-1RA and 3mu g/ml recombinant human R-Spondin-1. The culture medium disclosed by the invention can be used for carrying out separation culture or subculture on the normal epithelial cell of the human or the mammal and any other various tissue source, rapidly proliferating the normal epithelial cell in vitro and establishing a cell line; and the normal epithelial cell is a normal diploid cell and is applied to the toxicological evaluation system of the human or the mammal.

The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

The invention relates to a pigeon feed and a processing method thereof, belonging to the technical field of feeds and processing methods thereof. The pigeon feed is prepared from the following raw materials in parts by weight: 35-40 parts of corns, 15-20 parts of oats, 20-25 parts of green beans, 12-18 parts of barleys, 12-18 parts of wheat, 8-12 parts of sorghum, 8-10 parts of castor beans, 5-8 parts of houttuynia cordata, 5-8 parts of ajowan, 6-9 parts of momordica grosvenori, 4-9 parts of rhizoma atractylodis, 6-9 parts of orange peels, 3-7 parts of rhizoma alismatis and 4-8 parts of grifola. Due to the addition of dietary supplements formed by traditional Chinese medicines and water, the pigeon feed is capable of promoting the healthy and rapid growth of the pigeons, improving the immunity and the disease resistance of the pigeons, providing a certain function of preventing the common diseases such as cholera fowl and coccidiosis of the pigeons, making the edible pigeons be better in meat quality and making the ornamental pigeons be stronger in physique after feeding twice every day; the pigeon feed is particularly suitable for the pigeons in moulting period.

The invention discloses a limbal stem cell serum-free medium, consisting of the following raw materials (calculated by weight percent): DMEM/F12 60ml-90ml, BSA 0.5g-4g, EGF 1Mug-4Mug, insulin 0.1mg-1mg, hydrogen 20ug-100ug, cholera toxin 1ug-10ug, transferrin 0.1mg-1mg, selenious acid 0.1ug-1ug, GCLCM 10ml-40ml, penicillin 5*103IU-2*104IU and streptomycin 5*103IU-2*104IU. The invention adopts the method that the culture medium is added with fibroblast conditioned medium, and the nutritive factors are supplemented with the hormone and cytokine combination, fibroblast conditioned medium and BSA. As a result, the nutritive needs for long-time in-vitro expansion and cultivation of the limbal stem cell serum-free medium are satisfied, and the medium is serum-free and suitable for commercial production.

This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition.

The invention discloses a monoclonal antibody against virulent strain E2 protein of classical swine fever virus and a hybridoma cell strain secreting the monoclonal antibody. The hybridoma cell strain is obtained by using hog cholera lapinized virus vaccine strain E2 protein expressed by Baculovirus as tolerogen, selecting Shimen strain E2 protein as immunogen, immunizing mouse by cyclophosphamide immunosuppression method, carrying out cell fusion, and sieving hybridoma cell strain capable of stably secreting monoclonal antibody against E2 protein. The monoclonal antibody can react with Shimen strain and can produce specific reaction with virulent strain of classical swine fever viruses of 1.1, 2.1, 2.2 and 2.3 gene sub-groups. The monoclonal antibody has neutralization activity and does not react with hog cholera lapinized virus vaccine strain, so that the monoclonal antibody can be used for differentiating virulent strain of classical swine fever virus and hog cholera lapinized virus vaccine strain, which establishes the foundation for establishing a method for differentiating wild virus infection of classical swine fever and vaccine immunity and for researching the molecular difference between CSFV virulent strain and mild strain.

The invention discloses a medicine for curing hog cholera, which is composed of Melicope pteleifolia, Elephantopus Scaber, isatis root, Fructus Forsythiae, coptis root, rhubarb, aucklandia root, orientalis carbon, bark of tree peony root, figwort, rehmanniae radix, rhizoma anemarrhenae, Astragalus root, radix codonopsitis and Atractylodes macrocephaia according to certain ratio; the efficiency for curing the hog cholera can reach 94.7%, the recovery ratio can reach 90%, the medicine has no side effect and no recurrence after recovery, the action is immediate after using the medicine, the medicine material is easily obtained and the cost is low; thus being an ideal medicine for curing hog cholera.

The invention discloses a fluorescence quantitative PCR agent box for quick-quantitative detecting swine-fever virus and swine-fever rabbit weak-virus bacterin, the method and the application. The agent box overcomes the shortage in traditional and modern method and can effectively make quantitative detection and quality supervisory control.

The invention discloses a pigeon feed and a preparation method thereof, and relates to the technical field of feeds and processing methods thereof. The pigeon feed comprises the following raw materials: calcium powder, spiral shell, dried small shrimp, slaked lime, edible salt, shell powder, ginger, bee glue, wheat, buckwheat, broomcorn, corn, pea, mung bean, apium graveolens, momordica grosvenori, dried orange peel, rhizoma alismatis and grifola. The pigeon feed provided by the invention is capable of improving the immunity and ant-disease capability of the pigeons, and has a certain prevention function for the common diseases such as cholera fowl and coccidiosis of pigeons so as to prevent the pigeons from the diseases. The pigeon feed is balanced in nutrition; and the meat quality of the pigeons which eat the pigeon feed is better.

The invention belongs to the technical field of bacterial gene engineering of animals, and in particular relates to the construction of a recombinant salmonella choleraesuis strain which does not contain resistance markers and expresses major antigenic loci of porcine transmissible gastroenteritis virus, vaccine preparation and application. In the recombinant salmonella choleraesuis strain C500 (pYA-2SLN) which does not contain the resistance markers and expresses the major antigenic loci of the porcine transmissible gastroenteritis virus, the preservation No. is CCTCC NO: M 209189, and the strain misses asd genes which are necessary for the growth of salmonella choleraesuis and contains plasmid capable of expressing the asd genes, genes of an antigenic locus A, an antigenic locus D and an antigenic locus N321 of the porcine transmissible gastroenteritis virus in the strain. The invention also discloses a method for preparing the salmonella choleraesuis and porcine transmissible gastroenteritis vaccine by utilizing the recombinant strain and application thereof. The prepared recombinant vaccine can stimulate pigs to generate protective immune response for resisting the salmonella choleraesuis and the porcine transmissible gastroenteritis virus, and prevent the infection of the salmonella choleraesuis and the porcine transmissible gastroenteritis virus effectively.

The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6 or higher, for the manufacture of a nutritional or pharmaceutical composition for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a cholera toxin family member. Also provided is a method for providing a GOS fraction capable of inhibiting cholera toxin (Ctx) binding to GM1 and fractions obtainable thereby.

The invention discloses a method for preparing an indoor air virus pathogen invincible opponent. The indoor air virus pathogen invincible opponent prepared by menthol, thymol, weeping forsythia oil and radix bupleuri oil has the killing rate of between 76 and 99.9 percent to idemic encephalitis, influenza viruses, hand-foot-and-mouth disease, avian influenza, legionnella, pneumoniae, hepatitis C viruses, hepatitis A viruses, Staphylococcus albus, Staphylococcus aureus, Klebsiella pneumoniae, Candida albicans, typhoid viruses, Escherichia coli, cholera viruses, infectious germs and bacteria, and harmful germs and bacteria. The indoor air virus pathogen invincible opponent is mainly applied to rooms, schools, hospitals, hotels, air conditioners, automobiles, public places, and the like, and has obvious effect on the control of diseases such as influenza, upper respiratory tract infection. The indoor air virus pathogen invincible opponent has outstanding substantive characteristics and broad application prospect.

The invention relates to a traditional Chinese medicine feed additive for preventing and treating hog cholera. The traditional Chinese medicine feed additive is characterized in that the following traditional medicine raw materials in parts by weight are selected: 150 parts of purple perilla, 50 parts of pinellia ternate, 180 parts of isatis root, 100 parts of platycodon grandiflorum, 80 parts of radix bupleuri and 100 parts of corydalis tuber. A preparation method of the feed additive comprises the following steps that 300 parts of radix saposhnikoviae, 150 parts of schizonepeta, 150 parts of isatis root, 150 parts of fructus forsythiae, 100 parts of radix bupleuri and 100 parts of burdock are adopted, the materials are mixed and then crushed, or are mixed after being respectively crushed, and the materials are packed. A use method comprises the following steps that the traditional Chinese medicine feed additive is fed in a mixed way according to a ratio that the feed: additive=100:(0.6-1.2). The raw material medicine adopted by the traditional Chinese medicine feed additive has the effects of clearing away the heat and the toxic materials and dispelling wind and heat, and has the beneficial effects of safety, no toxic or side effect and obvious and reliable treatment effect on hog cholera.